Business Wire

MA-REINVEST-ROBOTICS

Share
Proposed “European AI Act” and “Machinery Product Regulation” Will Hamper Innovation, Stifle Small Businesses and Disrupt Manufacturing, Global Robotics Leaders Warn

The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics , the VDMA Robotics + Automation Association , EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals.

While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted:

  • The mandatory third-party certification requirements will slow tech innovation across Europe.
  • The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage globally.
  • Disruption risk to regional supply chain, manufacturing and logistics operations will rise if the proposals are implemented and adopted.
  • Compliance with regulation worldwide will become more complex and burdensome.

Dr. Susanne Bieller, General Secretary of the International Federation of Robotics, states, “The International Federation of Robotics calls on European policymakers to amend both drafts to balance the protection of citizens with the market’s need to adopt new technologies and ensure a level-playing field for companies. This is not purely a European issue, as the proposed regulations will severely impact all companies bringing robots to the European market. In the long run, the new regulations will be to the disadvantage of European companies, especially SMEs and startups.”

Patrick Schwarzkopf, Managing Director of the VDMA Robotics + Automation Association and Director of EUnited Robotics, comments: “The EU-Commission’s proposals include burdensome regulations of so-called ‘High-Risk AI’ and ‘High-Risk-machinery.’ They include the introduction of extensive mandatory third-party certification requirements, which will discourage the use of AI and slow down innovation across Europe.”

Dr. Esben Hallundbæk Østergaard, the CEO of REInvest Robotics and founder of Universal Robots, comments: “The proposed legislation will hold back European robotics innovation. This is particularly concerning given robotics is the one emerging tech segment where Europe still has an edge globally. Locally, the legislation will negatively affect thousands of small businesses, factories, and manufacturers that rely on robotics and AI to automate critical operations and overcome labor shortages.”

Recommended policy amendments include limiting the scope of the AI Act to essential human rights risks, relying on manufacturers’ self-declaration of conformity in both the AI-Act and Regulation on Machinery Products, increasing enforcement and governance of the existing approach of the machinery directive, and working to create a global framework that increases safety and ethics while maintaining a level playing field. The recent draft report published on the Regulation on Machinery products by the European Parliament’s Committee on Internal Market and Consumer Protection (IMCO) points in this direction by proposing to uphold the crucial principle of self-declaration.

“The approach of the current machinery directive is sufficient. The problem is with governance. We recommend focusing on ensuring that products on the market actually comply with the current EU law, not creating new regulations,” said Østergaard.

For more info, visit reinvestrobotics.com and watch Patrick Schwarzkopf and Dr. Esben Hallundbæk Østergaard discuss the proposals: https://youtu.be/cd0VQx6w-wQ

About REInvest Robotics

REInvest Robotics is a specialized accelerator that invests in startups that democratize the use of robotics to solve real world problems. Founded by robotics pioneer and inventor Esben Hallundbæk Østergaard and Richa Hallundbæk Misri, REInvest Robotics’ vision is to fuel the robotics ecosystem with sustainable investments and help entrepreneurs uplift humankind through robotics. The firm – which provides seed funding and advisory services – specializes in robotics, AI, manufacturing, safety standards and legislation. Successful investments include market leaders Universal Robots and Mobile Industrial Robots (MiR). Learn more at https://www.reinvestrobotics.com/ and follow REInvest Robotics on LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises18.11.2025 10:00:00 CET | Press release

Series A led by Creandum, with Elaia and Speedinvest, will accelerate the product development of GetVocal’s AI customer experience platform GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces. Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in bla

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye